Myovant Sciences downgraded by Evercore ISI
$MYOV
Biotechnology: Pharmaceutical Preparations
Health Care
Evercore ISI downgraded Myovant Sciences from Outperform to In-line
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/26/2022 | Outperform → In-line | Evercore ISI | |
| 8/9/2022 | $12.00 → $23.00 | Mkt Perform → Outperform | SVB Leerink |
| 2/16/2022 | $21.00 → $19.00 | Market Perform | SVB Leerink |
| 1/5/2022 | $23.00 → $21.00 | Market Perform | SVB Leerink |
| 10/27/2021 | $24.00 → $23.00 | Market Perform | SVB Leerink |
| 9/9/2021 | $24.00 | Market Perform | SVB Leerink |
| 8/20/2021 | $18.00 | Neutral | Goldman |
Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estimated at 13,500 through December 2022Myovant remains well-capitalized with cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement of $315.7 million
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant's 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE's Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 149,300 common shares of Myovant. One-fourth of the shares underlying each employee'
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant's global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant's Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a demonstrated history of working in pharmaceutical and biotech organizations building strategies and solutions across organizational and people development, employee recruitment, busine
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
Evercore ISI downgraded Myovant Sciences from Outperform to In-line
SVB Leerink upgraded Myovant Sciences from Mkt Perform to Outperform and set a new price target of $23.00 from $12.00 previously
SVB Leerink reiterated coverage of Myovant Sciences with a rating of Market Perform and set a new price target of $19.00 from $21.00 previously
15-12G - Myovant Sciences Ltd. (0001679082) (Filer)
EFFECT - Myovant Sciences Ltd. (0001679082) (Filer)
EFFECT - Myovant Sciences Ltd. (0001679082) (Filer)
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant's global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant's Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a demonstrated history of working in pharmaceutical and biotech organizations building strategies and solutions across organizational and people development, employee recruitment, busine
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom. "We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom," said Terrie Curran, President and Chief Executive Officer of Phathom. "Frank's financial, business